Literature DB >> 12018465

Antiinflammatory and immunomodulatory properties of statins.

Ora Shovman1, Yair Levy, Boris Gilburd, Yehuda Shoenfeld.   

Abstract

Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase or statins constitute the most powerful class of lipid lowering drugs, widely used in medical practice. During the past several years additional actions of statins unrelated to cholesterol reduction have been identified which includes antiinflammatory and immunomodulatory properties. Since atherosclerosis is a form of inflammation and the immune system play an important role in its pathogenesis, pleiotropic effect of statins may provide complementary explanation to their clinical benefit. This article reviews the data regarding the antiinflammatory and immunomodulatory properties of the statins that are available in the treatment of atherosclerosis and possibly may be applicable in other inflammatory diseases or conditions with the involvement of the immune system.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12018465     DOI： 10.1385/IR:25:3:271

Source DB:  PubMed          Journal:  Immunol Res        ISSN： 0257-277X            Impact factor:   2.829


  132 in total

1.  Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies.

Authors:  R Hoffman; G J Brook; M Aviram
Journal:  Atherosclerosis       Date:  1992-03       Impact factor: 5.162

2.  The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis.

Authors:  M J Davies; J L Gordon; A J Gearing; R Pigott; N Woolf; D Katz; A Kyriakopoulos
Journal:  J Pathol       Date:  1993-11       Impact factor: 7.996

Review 3.  Are there potential non-lipid-lowering uses of statins?

Authors:  D C Wheeler
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 4.  Chlamydia in coronary plaques--hidden culprit or harmless hobo?

Authors:  L Capron
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

5.  A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action.

Authors:  D Sumi; T Hayashi; N K Thakur; M Jayachandran; Y Asai; H Kano; H Matsui; A Iguchi
Journal:  Atherosclerosis       Date:  2001-04       Impact factor: 5.162

6.  Pravastatin down-regulates inflammatory mediators in human monocytes in vitro.

Authors:  O Grip; S Janciauskiene; S Lindgren
Journal:  Eur J Pharmacol       Date:  2000-12-20       Impact factor: 4.432

7.  Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies.

Authors:  M Aviram; G Dankner; U Cogan; E Hochgraf; J G Brook
Journal:  Metabolism       Date:  1992-03       Impact factor: 8.694

8.  Functionally abnormal monocytes in hypercholesterolemia.

Authors:  E Stragliotto; M Camera; A Postiglione; M Sirtori; G Di Minno; E Tremoli
Journal:  Arterioscler Thromb       Date:  1993-06

9.  Monocytes from patients with combined hypercholesterolemia-hypertriglyceridemia and isolated hypercholesterolemia show an increased adhesion to endothelial cells in vitro: II. Influence of intrinsic and extrinsic factors on monocyte binding.

Authors:  J F Jongkind; A Verkerk; N Hoogerbrugge
Journal:  Metabolism       Date:  1995-03       Impact factor: 8.694

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more
  16 in total

1.  Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells.

Authors:  A Iwata; R Shirai; H Ishii; H Kushima; S Otani; K Hashinaga; K Umeki; K Kishi; I Tokimatsu; K Hiramatsu; J Kadota
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

2.  The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats.

Authors:  I Ballester; A Daddaoua; R López-Posadas; A Nieto; M D Suárez; A Zarzuelo; O Martínez-Augustin; F Sánchez de Medina
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

3.  Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin.

Authors:  Andreia A Canalli; Renata F Proença; Carla F Franco-Penteado; Fabiola Traina; Tatiana M Sakamoto; Sara T O Saad; Nicola Conran; Fernando F Costa
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

Review 4.  The cardioprotective effects of statins.

Authors:  Jean Davignon
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

5.  Lipid-lowering effects of ethyl 2-phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in rodents.

Authors:  Justin M Holub; Kathy O'Toole-Colin; Adam Getzel; Anthony Argenti; Michael A Evans; Daniel C Smith; Gerard A Dalglish; Shahzad Rifat; Donna L Wilson; Brett M Taylor; Ulander Miott; Josephine Glersaye; Kam Suet Lam; Bryan J McCranor; Joshua D Berkowitz; Robert B Miller; John R Lukens; Keith Krumpe; John T Gupton; Bruce S Burnham
Journal:  Molecules       Date:  2004-02-28       Impact factor: 4.411

Review 6.  Fluvastatin: clinical and safety profile.

Authors:  Alberto Corsini; Terry A Jacobson; Christie M Ballantyne
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture?

Authors:  Raymond G Schlienger; Christoph R Meier
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.

Authors:  Anna Frisinghelli; Antonio Mafrici
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

9.  The Effect of Statins Use on the Risk and Outcome of Acute Bacterial Infections in Adult Patients.

Authors:  Mohammad Nassaji; Raheb Ghorbani; Reza Kiaee Afshar
Journal:  J Clin Diagn Res       Date:  2015-11-01

Review 10.  Statins and autoimmunity.

Authors:  Saakshi Khattri; Gisele Zandman-Goddard
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.